Is it useful to control blood pressure faster in hypertensive patients? Based on: Gradman AH et al. Hypertension. 2013;61:309-318.

Slides:



Advertisements
Similar presentations
©2011 MFMER | slide-1 Hipertensión Arterial Sistémica: Enfoque del Cardiólogo Jorge F. Trejo, MD, MHS Congreso Anual de Cardiología Internacional Guadalajara,
Advertisements

Get to Goal, Achieve Control
Heart Disease and Stroke Statistics 2011 Update 1.
G. Simonetti and F. Schaefer Pediatric Nephrology, Center for Pediatric and Adolescent Medicine, University of Heidelberg, Germany Management of High and.
Robert M. Guthrie, MD Professor of Emergency Medicine
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.
Treatment of hypertension: What are the new standards of care?
1 Hypertension 2002: An Overview. 2 Leading Risks For Death (World Health Organization 1995)
CE REVIEW UNDERSTANDING HYPERTENSION. Hypertension is a chronic medical condition affecting more than 65 million Americans. Controlling hypertension is.
1 Mark Huffman, MD, MPH Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital Healthy Transitions 21 November 2013 Blood Pressure.
Treatment-Resistant Hypertension: Magnitude of the Problem Power Over Pressure
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
The concept of Diabetes & CV risk: A lifetime risk challenge
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Hypertension: Blood Pressure Measurement and the new NICE guideline Prof Richard McManus BHS Annual Meeting Cambridge 2011 NICE clinical guideline 127.
1 Current & New treatment strategies to address CV Risk.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.
HvC Comparative Effectiveness Project Groups 5 and 6
A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.
VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
2007 Hypertension as a Public Health Risk January, 2007.
Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):
Blood pressure control: Where do we stand? Latest data from Italy Tocci G et al. J Hypertens. 2012;30:
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,
Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements Reference:
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Community Teaching Project: Hypertension Presented by: Mariel Alvarez, Michelle Vickers, Andy Nguyen, Lalita Poon, Minh Luong.
Antonio Coca, MD, PhD, FRCP, FESC
Dr John Cox Diabetes in Primary Care Conference Cork
Hypertension guidelines What’s all the controversy about 2015
Aaron P Kithcart Giuseppe Curigliano Joshua A. Beckman Cardio-Oncology
Blood Pressure and Age in Controlling Hypertension
Copyright © 2011 American Medical Association. All rights reserved.
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
Should SPRINT change our practice?
Copyright © 2007 American Medical Association. All rights reserved.
United States Preventive Services Task Force: Recommendations for ABPM
Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.
Circ Cardiovasc Qual Outcomes
Проценка на кардиоваскуларен ризик и препораки за третман
Teaching Tool: Blood Pressure Classification
Progress and Promise in RAAS Blockade
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Managing Complex Hypertension: What Every Physician Should Know
Hypertension Guidelines
MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Alan Gradman  Journal of Indian College of Cardiology 
Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.
Managing Blood Pressure
Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.
Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
JNC Evidence-Based Guideline for the Management of
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:
End point Valsartan Valsartan+HCTZ p
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

Is it useful to control blood pressure faster in hypertensive patients? Based on: Gradman AH et al. Hypertension. 2013;61:

Cardiovascular diseases vs hypertension 1 out 3 deaths is due to cardiovascular diseases (2007). 1 Hypertension is the 1 st risk factor of cardiovascular diseases. 2 Each increase of 20/10 mm Hg (SBP/DBP) doubles the risk of cardiovascular death. 3 International guidelines advise to control blood pressure below 140/90 mm Hg. 4 1.Roger VL et al. Circulation. 2011;123:e18-e Hobbs, Richard FD. Vasc Health Risk Manag. 2007;3: Lewington S et al; Prospective Studies Collaboration. Lancet. 2002;360: Mancia G et al. Eur Heart J. 2013;34:

Gradman et al study design 1762 adult patients with uncontrolled hypertension started on combination therapy (newly initiated on hypertensive therapy). Respectively analyzed through electronic medical chart ( ). Matched to an equal number of patients from the add-on therapy cohort (starting with monotherapy). Mean SBP/DBP of both cohorts 150/84 mm Hg at baseline. 54% of patients in each cohort had stage 1 hypertension. The study end points included risk of CV events or all-cause death, time to BP goal attainment,* and rates of health care resource use. *Time to BP goal attainment was defined as the time from treatment initiation to the first of two consecutive target BP readings <140/90 mm Hg or <130/80 mm Hg for patients with diabetes mellitus or CKD.

81% decrease of acute myocardial infarction, P<0.0001, in favor of combination therapy group Figure 1. Incidence rates and incidence rate ratios of cardiovascular events. 34% risk reduction for CV events and all-cause death with first- line combination compared to patients initiated on monotherapy and switched later to combination.

Median time to target BP achievement was 18.5% faster with combination than with initiation monotherapy P= (9.7 months vs 11.9 respectively) Figure 2. Kaplan-Meier estimates of achieving target blood pressure for each exposure group for all patients.

32% more time was needed to control BP in patients with CV events, median time to target BP achievement (10.6 months vs 15.8) P= Figure 3. Kaplan-Meier estimates of achieving target blood pressure for patients with and without a cardiovascular event during the follow-up for all patients.

Conclusion Median time to target BP achievement was 18.5% faster with first-line combination. 1 34% risk reduction for CV events and all-cause death with first-line combination compared to patients initiated on monotherapy and switched later to combination. 1 More rapid achievement of target BP was found to be the main contributor to the estimated risk reduction. 1 These results reinforce the 2004 VALUE study results on the need for an earlier blood pressure control and its direct link to CV event protection: “BP goals need to be reached within a relatively short time (weeks rather than months).” 2 “The blood pressure response after just 1 month of treatment predicted events and survival.” 3 This study enhance the need for an optimized combination to be prescribed in newly diagnosed patients to control blood pressure faster, in order to protect patients earlier from CV events. 1.Gradman AH et al. Hypertension. 2013;61: Julius S et al. Lancet. 2004;363(9426): Weber MA. Lancet. 2004;363: